Challenges and Opportunities in Immunotherapy of Malignant Solid and Liquid Tumors

Malignant solid tumors have an Age-Standardized Rate (World) per 100 000 of Mortality, Both sexes of 84.2 and of Malignant Liquid tumors of 6.1. The immunoregulation of Malignant solid and liquid tumors is the dynamic interaction between the immune system and tumor cells. This relationship is fundamental to understanding how the immune system can detect and eliminate cancer cells, as well as the mechanisms that tumors use to evade this surveillance. These mechanisms include reducing the immunogenicity of tumor cells and manipulating the tumor microenvironment to suppress the immune response, leading to tumor progression associated with immune suppression, interfering with the immune system's ability to respond effectively to cancer.

Understanding these processes has led to the development of immunotherapies, as they have been shown to be effective in a variety of cancers, including melanoma, lung cancer, bladder cancer and leukemias. Treatments can be used alone or in combination with chemotherapy or radiotherapy to improve clinical outcomes, and the combination of therapeutic approaches focused on modulating the immune system offers a promising path towards more effective and personalized treatments.

In this Research Topic, we want to promote and recognize research in cancer immunoregulation and the development of frontier immunotherapies. We are calling for original research papers, reviews, mini-reviews, case reports, brief research reports, data reports, opinion papers and perspective papers dealing with biomarkers improving the inmunotargeting of advanced Malignant solid and liquid tumour, with diagnosis, prediction and therapeutically purpose. We aim to provide a broad overview of the ongoing research in the Immunoregulation of cancer and immunotherapy world.

Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.